InvestorsHub Logo
Followers 7
Posts 1112
Boards Moderated 0
Alias Born 11/14/2017

Re: None

Wednesday, 12/20/2017 3:32:43 PM

Wednesday, December 20, 2017 3:32:43 PM

Post# of 12427
SUMMARY LXGTF : Lexington BioSciences (CSE: LNB) (OTCQB: LXGTF) is developing the HeartSentry, a new non-invasive diagnostic tool for accurately measuring and monitoring cardiovascular health.

• The HeartSentry measures the function of the endothelium – the critical inner lining of a person’s cardiovascular system.
• The core research and IP portfolio has been exclusively licensed to the company.
• Lexington is in final stages of releasing the product into clinical studies for FDA approval.
• The cardiovascular diagnostic market is growing fast and evolving into
personalized medicine.
• The goal is to make HeartSentry the standard of care for cardiologists, general practitioners, and ultimately patients first line evaluation of cardiovascular health.
• We seek the participation of dedicated stakeholders and committed
partners who share our vision of the future of cardiovascular personalized medicine.